For the week ending January 10, Alternatives Watch has tracked more than $1.8 billion in private financing deals done by private equity firms, institutional investors and hedge funds in the life sciences arena.
Some of the more well-known investors this past week include Tiger Global Management, Mirae Asset, New Enterprise Associates, Blackrock, Viking Global, Citadel's Surveyor Capital and others. All told these investors are supporting research in infectious disease, digital health and gene-based cancer therapy expansion.
The deals outlined are all of the financing rounds totaling $40 . . .